Filing Flows › Tela Bio (TELA) › Q2 2026 › vs Q1 2026
Tela Bio (TELA) Q2 2026 vs Q1 2026 (quarter over quarter)
Tela Bio's revenue rose $232K (+1%) from $19.1M in Q1 2026 to $19.3M in Q2 2026.
Tela Bio, Q2 2026: revenue $19.3M (-4% year over year), operating margin -48.1%, net loss $11.3M, operating cash flow −$9.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $19.3M | $19.1M | $232K | +1% |
| Net loss | $11.3M | $12.3M | −$1.0M | -8% |
| Costs & expenses | $30.6M | $31.3M | −$779K | -2% |
| Operating costs | $28.6M | $29.6M | −$1.0M | -3% |
| Interest & other, net | $1.9M | $1.7M | $232K | +14% |
| Income tax | $60K | $60K | $0 | 0% |
| Cost of revenue | $5.3M | $6.5M | −$1.2M | -18% |
| Research & development | $2.7M | $2.3M | $380K | +16% |
| Sales & marketing | $16.4M | $16.5M | −$95K | -0.6% |
| General & admin | $4.1M | $4.2M | −$105K | -3% |
| Operating cash sources | $11.3M | $12.3M | −$1.0M | -8% |
| Depreciation | $171K | $169K | $2K | +1% |
| Share-based compensation | $613K | $816K | −$203K | -25% |
| Working capital & other | $1.1M | $118K | $979K | +830% |
| Cash used in operations | $9.4M | $11.2M | −$1.8M | -16% |
| Net loss absorbed | $11.3M | $12.3M | −$1.0M | -8% |
Questions
How much did Tela Bio's revenue grow quarter over quarter in Q2 2026?
Tela Bio's revenue rose $232K (+1%) from $19.1M in Q1 2026 to $19.3M in Q2 2026.